AC
AI Cancer Cure

Evidence Atlas, updating nightly

Explore

Latest literature

Cancer research papers

Nightly index of recent papers from PubMed, bioRxiv, and medRxiv. Filters are designed for both researcher precision and patient-friendly navigation.

Learn how we rate papers in our methodology.

Starting focus

Cholangiocarcinoma

We’re indexing all cancers but highlighting cholangiocarcinoma while the evidence atlas expands.

View cholangiocarcinoma papers
3 papersSorted by most recent
Expert consensus on the detection and clinical application of tumor mutational burden.
Cancer biology & medicine • 2026-02-17 • DOI: 10.20892/j.issn.2095-3941.2025.0351
Peer-reviewedImpact 71

Topics

Treatment

Modality

Immunotherapy, Targeted therapy, Biomarker / Liquid biopsy, Imaging

Study type

Not listed

Abstract

As an emerging biomarker, tumor mutational burden (TMB) has attracted increasing attention from clinicians in predicting the efficacy of tumor immunotherapy. Currently, TMB is detected primarily by whole-exome sequencing or targeted panel sequencing on high-throughput sequencing platforms. However, the lack of uniformity in detection…

Authors

Zhenying Guo, Chunwei Xu, Shirong Zhang, Yue Hao +167

AI-generated summary

Expert consensus on the detection and clinical application of tumor mutational burden. reports: As an emerging biomarker, tumor mutational burden (TMB) has attracted increasing attention from clinicians in predicting the efficacy of tumor immunotherapy. Currently, TMB is detected primarily by whole-exome sequencing or targeted panel sequencing on high-throughput sequencing platforms. However, the lack of uniformity in detection methods, threshold settings, and reporting formats, as well as the significant differences in TMB values among different cancer types, have hindered the standardized application of this biomarker in clinical practice.

This summary may be inaccurate. Verify with the primary paper.

Primary source: PubMed.

Nanoheterojunction-Based Self-Powered Biosensor Integrated with Smartphones for Early Cancer Detection.
Advanced healthcare materials • 2026-02-17 • DOI: 10.1002/adhm.202505453
Peer-reviewedImpact 71

Topics

Diagnosis, Screening / Early detection, Biology / Mechanism, Outcomes / Survival

Modality

Biomarker / Liquid biopsy, Imaging

Study type

Not listed

Abstract

Early diagnosis of cancer is critical for improving patient survival rates. As biomarkers closely associated with tumorigenesis, microRNAs (miRNAs) remain challenging to detect with sufficient sensitivity, simplicity, and portability. This study presents a self-powered, dual-readout electrothermal biosensing chip that integrates an enzyme-free catalytic hairpin…

Authors

Jing Xu, Hanxiao Chen, Yifang Tao, Qichen Yuan +4

AI-generated summary

Nanoheterojunction-Based Self-Powered Biosensor Integrated with Smartphones for Early Cancer Detection. reports: Early diagnosis of cancer is critical for improving patient survival rates. As biomarkers closely associated with tumorigenesis, microRNAs (miRNAs) remain challenging to detect with sufficient sensitivity, simplicity, and portability. This study presents a self-powered, dual-readout electrothermal biosensing chip that integrates an enzyme-free catalytic hairpin assembly (CHA) amplification strategy with hierarchical SnO 2 @MoS 2 hollow spheres for highly sensitive and specific detection of microRNA-126 (miRNA-126).

This summary may be inaccurate. Verify with the primary paper.

Primary source: PubMed.

PreprintImpact 38

Topics

Treatment, Biology / Mechanism

Modality

Immunotherapy, Targeted therapy, Imaging

Study type

Not listed

Abstract

In recent years, it has been demonstrated that many of the pervasive genetic defects throughout cancerogenesis occur in genes encoding chromatin regulators (CRs). We analyzed the distribution and characteristics of well-studied CRs across tens of thousands of tumor samples. Our analysis revealed that tumors…

Authors

Kungulovski, G., Gjorgjievska, M., Mehandziska, S., Bukovec, D. +3

AI-generated summary

Tumors with mutations in chromatin regulators are associated with higher mutational burden and improved response to checkpoint immunotherapy reports: In recent years, it has been demonstrated that many of the pervasive genetic defects throughout cancerogenesis occur in genes encoding chromatin regulators (CRs). We analyzed the distribution and characteristics of well-studied CRs across tens of thousands of tumor samples. Our analysis revealed that tumors with mutations in CRs are associated with high tumor mutational burden (TMB). This is a preprint and not peer reviewed.

This summary may be inaccurate. Verify with the primary paper.

Primary source: medRxiv (not peer reviewed).